Smithkline Beecham Corporation

Beecham Group Plc

Other

Glaxo Group Limited

Glaxosmithkline LLC

Steven Dabbs

Eric Hunt

Colin Henry Frydrych

Barry S Orlek

Steven Mark Bromidge

Francis Dominic Sanderson

Gary Woodnutt

Valerie Joan Berry

David Thomas Davies

Gerald Brooks

Siegfried B Christensen, Iv

Paul Adrian Wyman

William Edward Bondinell

Steven Howard

Roderick Alan Porter

Neil David Pearson

Alan Joseph Hennessy

Joseph M Karpinski

Graham Elgin Jones

Harry J Wadsworth

Timothy James Miles

Israil Pendrak

Sarah Margaret Jenkins

Robert A Daines

Julia Castro Pichel

Joseph W Venslavsky

Jose Maria Fiandor Roman

James A Chan

Lihua Zhang

Steven Aitken

Lihua(lily) Zhang

James B Hoffman

Jason Anthony Rossi

Modesto J Remuiñan Blanco

David Barros

Lluis Ballell

Ilaria Giordano

Modesto J Remuinan Blanco

The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.

Pleuromutilin derivatives as antimicrobials

Bicyclic nitrogen containing compounds and their use as antibacterials.

Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones

Pleuromutilin compounds of the formula:are of use in anti-bacterial therapy.

Heterocyclic mutilin esters and their use as antibacterials

A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Compounds and methods

This invention relates to a method for preparing difluoromethyl ethers, thiols and amines without using chlorofluorocarbon gases. The intermediates prepared by this method can be used to make certain compounds which act as PDE IV inhibitors which are useful for treating asthma and other diseases implicated with the PDE IV isozyme.

Method for synthesis of aryl difluoromethyl ethers

A pharmaceutical composition useful to treating dementia which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which p is 1 and either m is 0 and n is 2 or 3 or m is 1 and n is 2, or p is 2, m is 0 and n is 2, and Z is a heterocyclic group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R.sub.1 ; or a group ##STR3## which A.sub.1, A.sub.2 and A.sub.3 complete a 5-membered aromatic ring and A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.2 and the other is nitrogen or CR.sub.3, or A.sub.2 is oxygen or sulphur, one of A.sub.1 and A.sub.3 is CR.sub.2 and the other is CR.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen, halogen, N(R.sub.4).sub.2, C.sub.2-3 alkenyl, C.sub.2-3 alkynyl or C.sub.1-2 alkyl optionally substituted with one, two or three fluorine atoms, in which R.sub.4 is hydrogen or methyl, and a pharmaceutically acceptable carrier.

Azabicyclic compounds with muscarinic activity useful for treating

1,2,5,6-tetrahydropyridine oxime derivatives

1,2,5,6-tetrahydropyridine oxime compounds

A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 represents ##STR2## in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;

Azabicylo oxime compounds

Growing community of inventors

Harlow, United Kingdom

Steven Dabbs